Skip to content
HowShorted

INOVIO PHARMACEUTICALS, INC. short interest in 2020

In 2020, INOVIO PHARMACEUTICALS, INC.'s disclosed short interest ran from 9.96% of shares outstanding on 15 Jan 2020 to 33.14% on 31 Dec 2020, a change of +23.18 percentage points. The year's high was 34.88% on 13 Nov 2020 and its low 9.96% on 15 Jan 2020, averaging 23.12% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.73 days on 30 Oct 2020. Full history: INOVIO PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for INOVIO PHARMACEUTICALS, INC. in 2020

2020 in figures

Start of year
9.96% (15 Jan 2020)
End of year
33.14% (31 Dec 2020)
Change
+23.18 pp
High
34.88% (13 Nov 2020)
Low
9.96% (15 Jan 2020)
Average
23.12%
Highest days to cover
10.73 (30 Oct 2020)
SEC filings marked
5

Every report in 2020

INOVIO PHARMACEUTICALS, INC. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 20209.96%9.89
31 Jan 202012.29%1.00
14 Feb 202013.01%1.46
28 Feb 202016.14%1.01
13 Mar 202014.81%1.00results (8-K), 10-K filed
31 Mar 202014.16%1.00
15 Apr 202014.20%1.47
30 Apr 202015.14%1.00
15 May 202015.72%1.0010-Q filed
29 May 202018.07%1.00
15 Jun 202017.68%1.48
30 Jun 202021.21%1.00
15 Jul 202020.30%1.00
31 Jul 202026.33%1.85
14 Aug 202028.23%2.5510-Q filed
31 Aug 202030.94%5.15
15 Sep 202034.16%4.07
30 Sep 202034.17%1.47
15 Oct 202032.85%6.98
30 Oct 202033.88%10.73
13 Nov 202034.88%5.2310-Q filed
30 Nov 202032.68%4.87
15 Dec 202031.02%4.61
31 Dec 202033.14%6.05

See also: INOVIO PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.